BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20661560)

  • 1. Management of local recurrence of colorectal cancer: the role of PET/CT.
    Bamba Y; Itabashi M; Kameoka S
    Abdom Imaging; 2011 Jun; 36(3):322-6. PubMed ID: 20661560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
    Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
    Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A treatment selection protocol for recurrent ovarian cancer patients: the role of FDG-PET/CT and staging laparoscopy.
    Fagotti A; Fanfani F; Rossitto C; Lorusso D; De Gaetano AM; Giordano A; Vizzielli G; Scambia G
    Oncology; 2008; 75(3-4):152-8. PubMed ID: 18827492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):324-8. PubMed ID: 19200683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of manual fusion of PET and CT images in patients with suspected recurrent colorectal cancer.
    Nakamoto Y; Sakamoto S; Okada T; Senda M; Higashi T; Saga T; Togashi K
    AJR Am J Roentgenol; 2007 Jan; 188(1):257-67. PubMed ID: 17179375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
    Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
    J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
    Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
    J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of carcinoembryonic antigen, magnetic resonance imaging, and positron emission tomography-computed tomography in the evaluation of patients with suspected local recurrence of colorectal cancer.
    Fiocchi F; Iotti V; Ligabue G; Malavasi N; Luppi G; Bagni B; Torricelli P
    Clin Imaging; 2011; 35(4):266-73. PubMed ID: 21724118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of 18-fluorodeoxyglucose positron emission/computed tomography in the management of recurrent colorectal cancer.
    Liong SY; Kochhar R; Renehan AG; Manoharan P
    ANZ J Surg; 2012 Oct; 82(10):729-36. PubMed ID: 22989147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of functional imaging in colorectal cancer.
    Figueiras RG; Goh V; Padhani AR; Naveira AB; Caamaño AG; Martin CV
    AJR Am J Roentgenol; 2010 Jul; 195(1):54-66. PubMed ID: 20566797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colorectal cancer: the role of PET/CT in recurrence.
    Vogel WV; Wiering B; Corstens FH; Ruers TJ; Oyen WJ
    Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S143-9. PubMed ID: 16361130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer.
    Arulampalam T; Costa D; Visvikis D; Boulos P; Taylor I; Ell P
    Eur J Nucl Med; 2001 Dec; 28(12):1758-65. PubMed ID: 11734912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DIAGNOSTIC ROLE OF FLUORINE-18 (18F) FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY IN DETECTING RECURRENT DISEASE IN PATIENTS WITH COLORECTAL CANCER AND ELEVATED CARCINOEMBRYONIC ANTIGEN.
    Matovina E; Mihailović J; Nikoletić K; Srbovan D
    Med Pregl; 2015; 68(11-12):376-81. PubMed ID: 26939303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
    Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.